GlassScriptPhysician profile
Buffie J Mock
NPI 1992776793
$3,903.05
in general payments reported to CMS, 2019-2025
13 companies · $500 in 2025
The $500 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $243 · 2021: $130 · 2022: $1,764 · 2023: $309 · 2024: $338 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,786.09 | 2019-2025 | Precision7, Total30, Dailies |
| Bausch & Lomb Americas INC. | $423.68 | 2022-2025 | Infuse, Scoutpro Osmolarity System, Xiidra |
| Johnson & Johnson Vision Care, INC. | $393.10 | 2019-2025 | Acuvue |
| Coopervision INC. | $330.38 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Oyster Point Pharma, INC. | $305.88 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $276.96 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $134.91 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $104.02 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $49.16 | 2020-2022 | |
| Shire North American Group INC | $41.67 | 2019 | |
| Alcon Research LLC | $25.96 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.61 | 2019 | |
| Allergan, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buffie Mock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.